EZH2 and amyotrophic lateral sclerosis: Interestingly, treatment of ALS iPSCs with EZH2 inhibitor, GSK126, significantly reduced the neuroprotective activity of the ALS iPSC-CM (Fig. 3d), while other inhibitors showed  no difference or non-statistical trend (Additional file 2: Figure S9c).